| Cat.No. | Name | Information |
|---|---|---|
| M4838 | TAK-242 (Resatorvid) | Resatorvid (TAK-242) is a selective TLR4 signaling inhibitor. Resatorvid inhibited the production of NO, TNF-α and IL-6 with IC50 values of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid down-regulates the expression of MyD88 and TRIF signaling molecules downstream of TLR4. Resatorvid inhibits autophagy and plays a key role in a variety of inflammatory diseases. |
| M11408 | Hydroxychloroquine | Hydroxychloroquine is a synthetic antimalarial agent that also inhibits Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine effectively inhibited SARS-COV-2 infection. |
| M9063 | TLR2-IN-C29 | C29 is a Toll-like receptor 2 (TLR2) inhibitor. C29 blocked HTLR2/1 and HTLR2/6 with IC50 values of 19.7 and 37.6 μM, respectively. |
| M42066 | Polyinosinic acid | Polyinosinic acid is a single stranded homonucleic acid, which is a Toll-like Receptor 3 (TLR3) agonist. |
| M5062 | Polyinosinic:polycytidylic acid | Polyinosinic:polycytidylic acid (poly I:C) is a synthetic polyinosinic-polycytidylic acid double-stranded RNA. Polyinosinic-polycytidylic acid (Poly (I:C)) is an agonist of toll-like receptor (TLR)-3. Polyinosinic-polycytidylic acid has protective effects against cerebral ischemia/reperfusion (I/R) injury and can be used as vaccine adjuvant to enhance innate and adaptive immune responses. |
| M31226 | Chitohexaose hexahydrochloride | Chitohexaose hexahydrochloride is a chitosan oligosaccharide with anti-inflammatory effect. Chitohexaose hexahydrochloride binds to the active sites of TLR4 and inhibits LPS induced inflammation. |
| M30937 | ODN 1018 | ODN 1018 (1018 ISS), an oligodeoxynucleotide, is a TLR-9 agonist. ODN 1018 is also a synthetic immunostimulatory sequence that can be used as vaccine adjuvant. Sequence: 5′-TGACTGTGAACGTTCGAGATGA-3′. |
| M30420 | 3M-011 | 3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action. |
| M29946 | L48H37 | L48H37 is an analog of Curcumin with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment. |
| M29890 | MMG-11 | MMG-11 is a potent and selective human TLR2 antagonist with low cytotoxicity. MMG-11 inhibits both TLR2/1 and TLR2/6 signaling with IC50s of 1.7 µM for Pam3CSK4-induced hTLR2/1 and 5.7 µM for Pam2CSK4-induced hTLR2/6 responses. |
| M29713 | CL075 | CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively. |
| M29589 | Polvitolimod | Polvitolimod is a TLR7 agonist for research of cancer and infectious disease. |
| M29469 | SM-360320 | SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response. SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity. |
| M28075 | TLR7/8 agonist 1 | TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline. |
| M28000 | GSK1795091 | GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. |
| M27994 | TLR7 agonist 3 | TLR7 agonist 3 (Compound 2) is a potent agonist of toll-like receptor 7 (TLR7). TLR7 has an important role in immune activation processes and represents an emerging agent discovery target for the development of immunomodulators. |
| M27993 | BBIQ | BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses. |
| M27867 | Gardiquimod diTFA | Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μM. |
| M27847 | TMX-201 | TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research. |
| M27651 | Gardiquimod | Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10 μM. |
| M25485 | Diprovocim | Diprovocim is a potent human and mouse Toll-like receptor (TLR)1/TLR2 agonist, which exhibited an EC50 of 110 pM in human THP-1 cells and 1.3 nM in primary mouse peritoneal macrophages. Diprovocim activates downstream MAPK and NF-κB signaling pathway. |
| M25199 | Paridiprubart | Paridiprubart (NI-0101) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart has the potential for the research of rheumatoid arthritis. |
| M24686 | Tomaralimab | Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS). |
| M20017 | CL-104773 | CL-104773 is a TLR2 antagonist |
| M14129 | MMG-11 quarterhydrate | MMG-11 quarterhydrate is a potent and selective human TLR2 antagonist with low cytotoxicity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
